Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine and intracranial pressure / early cognitive function in breast cancer surgery
ChiCTR2200057986Phase 4Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in breast cancer, post-operative cognitive decline (POCD) and postoperative pain (2 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Diameter of optic nerve under ultrasound. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
breast cancerpost-operative cognitive decline (POCD)postoperative pain
Beyond the preview
Go deeper on ChiCTR2200057986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057986.